Skip to Content
Merck

294R-1

BOB.1 (SP92) Rabbit Monoclonal Antibody

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
SP92, monoclonal
Application:
IHC (p)
Citations:
14
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

SP92, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (294R-14), vial of 0.5 mL concentrate (294R-15), bottle of 1.0 mL predilute (294R-17), vial of 1.0 mL concentrate (294R-16), bottle of 7.0 mL predilute (294R-18)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

isotype

IgG1

control

B-cell lymphoma, tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Gene Information

human ... POU2AF1(5450)

General description

Expression of BOB.1/OBF.1 is restricted largely to mature B-cells. Germinal center B-cells normally demonstrate strong staining for BOB.1, as do mantle-zone B-cells, and plasma cells. Analyses of BOB.1/OBF.1 expression in a variety of established B-cell lines representing different stages of B-cell development has suggested a constitutive, B-cell-specific expression pattern. Because they are germinal center derived, L&H cells in nodular lymphocyte predominant Hodgkin lymphoma are consistenty immunoreactive for BOB.1. Conversely, the Hodgkin/Reed- Sternberg cells in classical Hodgkin lymphoma either do not express both (80%) or express only one (20%) of the two proteins. In B-cell lymphomas, the highest expression levels for BOB.1/OBF.1 are reported in follicular center lymphomas, diffuse large B-cell lymphomas and Burkitt lymphomas.B-CLL, MALT-type, and mantle cell lymphomas score negative or display an heterogenous/weaker reactivity.10-11 Studies have suggested that anti-BOB. has a high predictive value in discriminating primary mediastinal B-cell lymphoma from classical Hodgkin disease.Approximately 50% of acute myeloid leukemias express BOB.1.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

BOB.1 Positive Control Slides, Product No. 294S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Try our Product Selector Tool to narrow your options




Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Susanne Annette Steimle-Grauer et al.
Virchows Archiv : an international journal of pathology, 442(3), 284-293 (2003-03-21)
The World Health Organization (WHO) classification of Hodgkin lymphoma (HL) distinguishes two types: Classical Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Both groups have in common that they mostly derive from B cells with rare classical cases
Christina B Hertel et al.
Oncogene, 21(32), 4908-4920 (2002-07-16)
In classical Hodgkin lymphoma the malignant Hodgkin/Reed-Sternberg (HRS) cells characteristically constitute only a small minority of the tumour load. Their origin has been debated for decades, but on the basis of rearrangement and somatic hypermutations of their immunoglubulin (Ig) genes
H Stein et al.
Blood, 97(2), 496-501 (2001-01-12)
In contrast to the tumor cells (L&H cells) of lymphocyte predominant Hodgkin disease (LPHD), Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin disease (cHD) are unable to transcribe immunoglobulin, despite the presence of rearranged immunoglobulin genes. Although initial studies have